$PCRX

WILLIAMS KRISTEN sold $228K of PCRX

WILLIAMS KRISTEN (Chief Administrative Officer) sold 10,259 shares of Pacira BioSciences, Inc. (PCRX) at $22.27 ($0.23M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WILLIAMS KRISTEN
Published Jun 5, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PCRX
Neutral
medium confidence
Mentioned
$PCRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCRXNeutralLow
01

Why it matters

The disclosure updates insider activity records but does not introduce new fundamentals (no earnings, trial, approval, or deal information).

02

Market read

Near-term trading impact is likely limited; any sentiment effect should be weighed against the 10b5-1 pre-arranged nature.

03

What to watch

Traders may overreact to insider selling; without accompanying buys, guidance changes, or material events, the signal is weak.

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-05 after the sale executed on 2026-06-04

Background

SEC Form 4 reports insider transactions; this filing is an officer open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$PCRXNeutralMedium confidence
Context

Pacira BioSciences disclosed an officer open-market sale of 10,259 shares at $22.27 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 shows a scheduled open-market sale by a Chief Administrative Officer; no new operating, regulatory, or financial information is provided.

Market effects

Minimal; single-company insider transaction without new clinical/commercial/regulatory signals.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be routine liquidity events and may not reflect bearish expectations.

Key entities

  • Pacira BioSciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Kristen Williams

    Chief Administrative Officer who sold 10,259 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTRSHighAI 9/10

Viatris to Acquire Pacira in US$1.65bn Pain Management Deal

Viatris (VTRS) announced plans to acquire Pacira BioSciences (PCRX) for approximately US$1.65bn. Pacira generated US$746m in revenue over the last 12 months. The deal aims to strengthen Viatris' portfolio in non-opioid pain management, adding Pacira's Exparel and Zilretta to its offerings. The acquisition is expected to be immediately accretive and is set to close by the end of 2026.

$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

$VTRSHighAI 9/10

Viatris to Acquire Pacira Biosciences for USD 1.65 Billion, Adds Exparel, Zilretta to Pain Portfolio

Viatris (VTRS) will acquire Pacira Biosciences (PCRX) for $1.65B, or $36.50 per share, a 44.8% premium. Pacira shares rose 44%, Viatris fell 2%. The deal adds Exparel and Zilretta to Viatris' pain portfolio, with 2025 sales of $575.1M and $116.6M. Viatris plans to fund the deal with cash and short-term borrowings, expecting minimal leverage impact and immediate accretion.